Skip to content
Increase font size Default font size Decrease font size
patient Information for patients.
doctor Information for scientists and medical professionals.
brokers Information for investors.

Ovarian Cancer - Phase I/IIa Clinical Trial of BC-819

 

For information on this trial in Hebrew, click here for the Israel Cancer Association (external link)

 

Trial Objective

This open-label, dose escalation Phase I/IIa trial is designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of BC-819 administered intraperitoneally in patients with advanced stage ovarian cancer, or primary peritoneal carcinoma.

Inclusion/Exclusion Criteria

To be eligible to participate in this study, patients must meet a number of inclusion/exclusion criteria.

Treatment

Patients will receive 12 weekly treatments of BC-819 intraperitoneally, using a catheter previously placed in an operation.

Enrollment information

Current trial locations are:

# Medical Center Location Principal Investigator Contact Details
1 Hadassah Jerusalem, Israel David Edelman, MD 02-642-7485
2 Wolfson Holon, Israel Tally Levy, MD 03-502-8717
3 Meir Kfar Saba, Israel Ami Fishman, MD 09-747-2561
4 Carmel Haifa, Israel Ofer Lavie, MD 04-825-0637
5 Beilinson (Rabin) Petach Tikvah, Israel Eitan Ram, MD 03-937-7550
6 Sheba Tel Hashomer, Israel Ronnie Shapira-Frommer, MD 03-530-8414


For more information fill the information request form. Continue to check this website, as trial information and locations are being updated periodically. Information about BioCancell's clinical trials is also available at ClinicalTrials.gov (external link).